Kolexia
Araujo Carla Hématologie
Araujo Carla
Hématologie
Cabinet libéral
Bayonne, France
82 Activités
15 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Anémie Lymphomes Thrombopénie Lymphome folliculaire Hypertension artérielle Pneumopathie infectieuse Neutropénie

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France
Facon Thierry
Facon Thierry
Hôpital Huriez, Lille, France
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France

Industries

Voir plus
Janssen
10 collaboration(s)
Dernière en 2023
Celgene
4 collaboration(s)
Dernière en 2022
Amgen
2 collaboration(s)
Dernière en 2023
AstraZeneca
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03
65th ASH Annual Meeting Abstracts   02 novembre 2023
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01
65th ASH Annual Meeting Abstracts   02 novembre 2023
Carla Araujo - Facebook
Facebook   24 septembre 2023
PCD: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Essai Clinique (Celgene)   03 juillet 2023
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Haematologica   01 mai 2023
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   18 avril 2023
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
British journal of haematology   27 mars 2023
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Essai Clinique (Takeda Pharmaceutical)   07 février 2023
FLIRT: A Randomized Phase III Trial Evaluating Two Strategies of Rituximab Administration for the Treatment of First Line/Low Tumor Burden Follicular Lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy)
Essai Clinique (Roche)   09 janvier 2023
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
Annual Meeting Abstracts 2022   15 novembre 2022